The authors framed menopause as a neurobiological transition with measurable effects on brain function. Short-term subjective cognitive complaints rise during perimenopause. Many patients report memory lapses and slowed recall. Investigators reported that hypoestrogenism contributes to these complaints, but so do secondary phenomena—sleep disturbance, vasomotor symptoms, and mood changes. Objective neuropsychological deficits, however, are uncommon in the cohorts described; the study team observed that cognitive symptoms are often transient and rarely reflect progressive decline. The review did not present new randomized trial data quantifying long-term dementia risk attributable to menopause; it positioned clinical cognitive concerns as frequently reversible or nonprogressive in the perimenopausal window.
Data indicated that both endogenous hormonal shifts and exogenous sex hormones across the menopausal transition may alter seizure susceptibility. The authors discussed that changing estrogen and progesterone levels—plus an altered estrogen-to-progesterone ratio—can affect seizure thresholds. They also noted that menopause can modify antiseizure medication metabolism, potentially requiring dose reassessment. The source did not report specific antiseizure drug pharmacokinetic parameters or standardized dosing algorithms for menopause-related changes. Clinicians are advised to monitor seizure frequency and therapeutic levels and to consider endocrine influences when counseling patients about hormone therapies.
Migraine expression changes across the transition. The review indicated that migraine often worsens during perimenopause, particularly among estrogen-sensitive phenotypes. Once women enter postmenopause and hormone levels stabilize, migraine frequency and severity typically stabilize as well. The authors highlighted that menstrual and perimenopausal hormone variability explains much of this pattern. The article did not detail headache-specific interventional trials tied to menopause hormone therapy (MHT) beyond noting general phenotype associations; therefore, individualized headache management and careful discussion of MHT risks and benefits remain central.
Investigators reported that perimenopause and postmenopause represent periods of heightened clinical need in multiple sclerosis (MS). The cohort described overlapping age-related and MS-related symptoms that complicate assessment—fatigue, cognitive complaints, and mobility issues may reflect both processes. The review team observed that disability progression can accelerate during and after the menopausal transition despite a reduced relapse rate. The authors did not publish numerical progression rates or trial-derived effect sizes in the abstract; they emphasized the clinical observation that menopause timing and hormonal milieu should factor into MS care planning and symptom management.
The review summarized a pronounced rise in ischemic stroke risk in postmenopausal women. Investigators attributed this increase to three converging factors: advancing age, cumulative cardiometabolic risk, and loss of estrogen’s vascular effects. Regarding menopause hormone therapy (MHT), the authors reported that oral estrogen-containing systemic regimens are associated with increased thromboembolic events, including stroke. By contrast, transdermal estrogen formulations appeared safer in observational data and are preferred at low or standard doses; the review cited transdermal dosing ranges it considered low/standard (≤50 mcg estradiol patch or ≤1.5 mg per day of 0.06% estradiol gel, or the equivalent of 2 pumps daily). Timing of initiation was described as a critical modifier of vascular risk, with a more favorable risk:benefit profile when MHT is started in women younger than 60 years or within 10 years of menopause onset. The abstract did not include randomized trial-level stroke incidence figures or absolute risk estimates in the text provided.
The review aims to serve as a resource for neurologists managing patients through menopause. Authors recommended assessing the interplay of hormone status with neurologic symptoms and treatments: reevaluate seizure control and antiseizure drug levels when hormone status changes; screen for cognitive complaints and target reversible contributors such as sleep and mood disorders; consider migraine phenotype when discussing MHT; and explicitly weigh vascular risk factors when counseling about systemic oral estrogen. The review signaled preference for transdermal MHT when systemic estrogen is indicated and when vascular risk is a concern. The source did not provide a protocolized checklist or decision tree, so clinicians must integrate the review’s principles with individual patient risk profiles and specialty guidance.
The authors acknowledged limits intrinsic to a review format: the abstract did not present new randomized controlled trial data, nor did it supply detailed numeric outcomes, p-values, or cohort sizes. Specific pharmacokinetic details for antiseizure drugs across menopause were not provided in the abstract, and comprehensive head-to-head comparative data for oral versus transdermal MHT were not included in the text available. Key unanswered clinical questions—optimal MHT regimens for neurologic syndromes, the magnitude of long-term cognitive risk attributable solely to hypoestrogenism, and mechanistic links between menopause and MS progression—remain open and were identified as areas requiring further study in full text.
The review advances a practical, clinically oriented synthesis: menopause meaningfully affects cognition, seizure disorders, migraine, MS, and stroke risk, and hormone therapy choices—formulation, dose, and timing—alter risk profiles. Neurologists should incorporate these considerations into routine care, while recognizing the need for trial-level evidence that the abstract did not supply.